A real-world study reports that Nefecon (targeted-release budesonide) reduced proteinuria and helped preserve kidney function in primary IgA nephropathy. The analysis also includes patients starting with relatively low proteinuria levels, aiming to clarify whether benefit extends beyond typical high-proteinuria populations. The findings are presented as practical evidence for how the regimen performs outside tightly controlled trial environments, where adherence, baseline risk, and monitoring patterns differ. For nephrology stakeholders, proteinuria reduction remains a key surrogate linked to long-term renal outcomes, so real-world confirmation can influence adoption and prescribing behavior.